NasdaqCM:CORTPharmaceuticals
A Look At Corcept Therapeutics (CORT) Valuation After FDA Setback And Growing Legal Scrutiny
Corcept Therapeutics (CORT) is under pressure after the FDA issued a Complete Response Letter for relacorilant, questioning its effectiveness and safety, while several law firms have launched securities investigations related to the company’s communications.
See our latest analysis for Corcept Therapeutics.
At a share price of US$40.83, Corcept’s recent 1 month share price return of 9.29% contrasts with a 46.10% decline over 3 months and a 41.80% fall in 1 year total shareholder return...